Objectives: Clozapine is quite effective to treat schizophrenia, but its use is complicated by several factors. Although many patients respond to antipsychotic therapy, about 50% of them exhibit inadequate response, and ineffective medication trials may entail weeks of unremitted illness, potential adverse drug reactions, and treatment nonadherence. This review of the literature sought to describe the main pharmacogenetic studies of clozapine and the genes that potentially influence response to treatment with this medication in schizophrenics. Methods: We searched the PubMed database for studies published in English in the last 20 years using keywords related to the topic. Results and Conclusions: Our search yielded 145 studies that met...
There is still much to learn about the predictors of therapeutic response in psychiatry, but progres...
Introduction: Genetic polymorphisms of cytochrome P450 (CYP) may predict the treatment response or o...
Schizophrenia is a severe neuropsychiatric disorder that affects approximately 0.5-1% of the populat...
OBJECTIVE: Clozapine response varies widely from person to person, which may be due to inter-individ...
There is strong evidence to suggest that genetic variation plays an important role in inter-individu...
Up to 30% of people with schizophrenia do not respond to two (or more) trials of dopaminergic antips...
Clozapine is an efficacious atypical antipsychotic for treatment-refractory schizophrenia. Clinical ...
Schizophrenia is one of the most devastating mental and neuropsychiatric disorder that affects almos...
Aim: This review summarises the present knowledge of associations between pharmacogenetics and thera...
Altered glutamatergic neurotransmission is implicated in schizophrenia etiology and response to the ...
There is substantial unexplained interindividual variability in the drug treatment of schizophrenia....
Treatment-resistant schizophrenia is diagnosed after unsuccessful trials of two or more antipsychoti...
grantor: University of TorontoClozapine, the prototype of atypical antipsychotic drugs, is...
Clozapine is an efficacious atypical antipsychotic for treatment-refractory schizophrenia. Clinical ...
We did association studies in multiple candidate genes to find the combination of polymorphisms that...
There is still much to learn about the predictors of therapeutic response in psychiatry, but progres...
Introduction: Genetic polymorphisms of cytochrome P450 (CYP) may predict the treatment response or o...
Schizophrenia is a severe neuropsychiatric disorder that affects approximately 0.5-1% of the populat...
OBJECTIVE: Clozapine response varies widely from person to person, which may be due to inter-individ...
There is strong evidence to suggest that genetic variation plays an important role in inter-individu...
Up to 30% of people with schizophrenia do not respond to two (or more) trials of dopaminergic antips...
Clozapine is an efficacious atypical antipsychotic for treatment-refractory schizophrenia. Clinical ...
Schizophrenia is one of the most devastating mental and neuropsychiatric disorder that affects almos...
Aim: This review summarises the present knowledge of associations between pharmacogenetics and thera...
Altered glutamatergic neurotransmission is implicated in schizophrenia etiology and response to the ...
There is substantial unexplained interindividual variability in the drug treatment of schizophrenia....
Treatment-resistant schizophrenia is diagnosed after unsuccessful trials of two or more antipsychoti...
grantor: University of TorontoClozapine, the prototype of atypical antipsychotic drugs, is...
Clozapine is an efficacious atypical antipsychotic for treatment-refractory schizophrenia. Clinical ...
We did association studies in multiple candidate genes to find the combination of polymorphisms that...
There is still much to learn about the predictors of therapeutic response in psychiatry, but progres...
Introduction: Genetic polymorphisms of cytochrome P450 (CYP) may predict the treatment response or o...
Schizophrenia is a severe neuropsychiatric disorder that affects approximately 0.5-1% of the populat...